Preparation And Characterization Of Composite Hollow Fiber Reverse Osmosis Membranes By Plasma Polymerization. 2. Reproducibility Of The Plasma Polymerization Process And Durability Of The Resulting Coated Membrane

The reproducibility of the plasma polymerization process was examined in a semicontinuous coating of hollow fibers, 6 fibers in lengths of approximately 12-15 m, by evaluating the performance of reverse osmosis membranes. The uniformity of the coating along the length of hollow fibers, as well as the reproducibility of the process, was found to be satisfactory when electrodes were conditioned in the actual conditions of plasma polymerization to be employed and plasma polymerization conditions were carefully controlled. The durability of the coated hollow fibers was then investigated in the following test media: hot water, low pH, high pH, and 0.1% NaOCl solutions. A threshold value of glow discharge parameter W/FM was found to be crucial In the performance of the reverse osmosis membrane and durability of the coated hollow fibers. Plasma polymerized composite membranes showed remarkable durability. © 1984, American Chemical Society. All rights reserved

Mathematical Modelling in PET Studies

開始ページ、終了ページ: 冊子体のページ付

Tumor Uptake Studies of S-Adenosyl-L-[methyl-11C]Methionine and L-[methyl-11C]Methionine

開始ページ、終了ページ: 冊子体のページ付

Biochemical Investigation of 18F-Labeled Pyrimidines and 3H-Deoxythymidine in Tumor-Bearing Rats and Mice

開始ページ、終了ページ: 冊子体のページ付

SIAH1 (siah E3 ubiquitin protein ligase 1)

Review on SIAH1 (siah E3 ubiquitin protein ligase 1), with data on DNA, on the protein encoded, and where the gene is implicated

Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers

The met proto-oncogene is the tyrosine kinase growth factor receptor for hepatocyte growth factor. In the present study, we investigated the role of met expression on the modulation of apoptosis in colorectal tumours. The gene expressions of c- met and the anti-apoptotic bcl -2 family, including bcl -2, bcl -x L and bcl-w, were analysed in human colorectal adenomas and adenocarcinomas by using a quantitative polymerase chain-reaction combined with reverse transcription. In seven of 12 adenomas and seven of 11 carcinomas, the c- met gene was overexpressed. The bcl -w, bcl -2 and bcl -x L genes were over-expressed in nine, five and six of 12 adenomas and in five, two and seven of 11 carcinomas, respectively. The c- met mRNA level in human colorectal adenomas and carcinomas was correlated with bcl -w but not with bcl -2 or with bcl -x L mRNA level. The administration of c- met -antisense oligonucleotides decreased Met protein levels in the LoVo human colon cancer cell line. In the case of c- met -antisense-treated cells, apoptotic cell death induced by serum deprivation was more prominent, compared to control or c- met -nonsense-treated cells. Treatment with c- met -antisense oligonucleotides inhibits the gene expression of bcl -w in LoVo cells. On the other hand, the gene expression of bcl -2 or bcl -x L was not affected by treatment with c- met -antisense oligonucleotides. These findings suggest that Met expression modulates apoptosis through bcl -w expression in colorectal tumours. © 2000 Cancer Research Campaig

The Structure of the X-Ray Emitting Gas in the Hydra-A Cluster of Galaxies

The temperature and abundance structure in the intracluster medium (ICM) of the Hydra-A cluster of galaxies is studied with ASCA and ROSAT. The effect of the large extended outskirts in the point-spread function of the X-Ray Telescope on ASCA is included in this analysis. In the X-ray brightness profile, the strong central excess above a single beta-model, identified in the Einstein and ROSAT data, is also found in the harder energy band (>4keV). A simultaneous fit of five annular spectra taken with the GIS instrument shows a radial distribution of the temperature and metal abundance. A significant central enhancement in the abundance distribution is found, while the temperature profile suggests that the ICM is approximately isothermal with the temperature of ~3.5keV. The ROSAT PSPC spectrum in the central 1'.5 region indicates a significantly lower temperature than the GIS result. A joint analysis of the GIS and PSPC data reveals that the spectra can be described by a two temperature model as well as by a cooling flow model. In both cases, the hot phase gas with the temperature of ~3.5keV occupies more than 90% of the total emission measure within 1'.5 from the cluster center. The estimated mass of the cooler (0.5-0.7keV) component is ~2-6 x 10^9 M_solar, which is comparable to the mass of hot halos seen in non-cD ellipticals. The cooling flow model gives the mass deposition rate of 60+-30 M_solar/yr, an order of magnitude lower than the previous estimation.Comment: 27 pages, 14 figures, AAS LATEX macros v4.0, to appear in The Astrophysical Journa

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients <71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200 mg−1d for 2 months. Patients were then randomly assigned to control (n = 42) and pravastatin (n = 41) groups. Pravastatin was administered at a daily dose of 40 mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 ± 9.8 months (mean ± SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (P = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment. © 2001 Cancer Research Campaign http://www.bjcancer.co